Get the Stockscreener App
17.30
2.86%
-0.51
Apellis Pharmaceuticals Inc stock is traded at $17.30, with a volume of 2.96M.
It is down -2.86% in the last 24 hours and down -11.78% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$17.81
Open:
$17.52
24h Volume:
2.96M
Relative Volume:
1.34
Market Cap:
$2.56B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-8.5222
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-14.95%
1M Performance:
-11.78%
6M Performance:
-42.29%
1Y Performance:
-59.31%
1-Day Range:
$17.23
$18.10
1-Week Range:
$16.65
$20.59
52-Week Range:
$16.65
$43.99
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
17.30 | 2.56B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Raymond James Downgrades Apellis Pharmaceuticals (BIT:1APLS) - Nasdaq
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Pri - GuruFocus
Sector Update: Health Care - marketscreener.com
Apellis Pharmaceuticals Stumbles Over Funding And Sales Hurdles - Finimize
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News - GuruFocus
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securit - GuruFocus
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’ - Investing.com Canada
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? - Insider Monkey
Apellis (APLS) Faces Downgrade Amid Sales Volatility Concerns | - GuruFocus
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers - simplywall.st
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - MSN
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capi - GuruFocus
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capital | APLS Stock News - GuruFocus
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down - Zacks Investment Research
Apellis (APLS) Price Target Reduced by Scotiabank Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Price Target Lowered by Scotiabank | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS): Wells Fargo Lowers Price Target to $26 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals (APLS) Target Price Lowered by Analyst | APLS Stock News - GuruFocus
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks - TipRanks
Apellis Pharmaceuticals (APLS) Price Target Reduced by Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ... - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - Barchart.com
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Why Apellis Pharmaceuticals (APLS) Stock is Declining - GuruFocus
Why Apellis Pharmaceuticals Wilted on Wednesday - MSN
Why Apellis Pharmaceuticals Wilted on Wednesday - The Motley Fool
APLS: Apellis Pharmaceuticals Maintains Buy Rating Amid Price Target Cut | APLS Stock News - GuruFocus
Transcript : Apellis Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates By Investing.com - Investing.com Nigeria
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates - Investing.com
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues By Investing.com - Investing.com India
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - The Manila Times
Apellis (APLS) Sees Q1 Revenue Miss as Strategic Growth Continues | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BRIEF-Apellis Pharmaceuticals Q1 Basic EPS USD -0.74 - TradingView
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - TradingView
Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - Louisiana First News
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Apellis Pharmaceuticals to Present Q1 2025 Results: Complement Medicine Leader's Financial Update - Stock Titan
Apellis (APLS) Receives Overweight Rating and Positive Outlook f - GuruFocus
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):